A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years
NCT01847287 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2013-05-07
Summary
The primary aim of this study is to evaluate the effect of using Tysabri on changes in the brain using MRI and on disease progression in patients with relapsing-remitting Multiple Sclerosis over 5 years.
Conditions
Sponsors & Collaborators
-
University at Buffalo
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-05-31
- Primary Completion
- 2013-02-28
- Completion
- 2013-02-28
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis
NCT02904876 ·Status: TERMINATED ·Phase: PHASE4
-
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
NCT03046251 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
NCT03689972 ·Status: COMPLETED ·Phase: PHASE3
-
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
NCT01695434 ·Status: COMPLETED
-
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01440101 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
NCT00027300 ·Status: COMPLETED ·Phase: PHASE3
-
Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
NCT01250678 ·Status: UNKNOWN
-
Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab
NCT04964700 ·Status: UNKNOWN
-
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
NCT01881191 ·Status: COMPLETED
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT05265728 ·Status: TERMINATED ·Phase: PHASE3
-
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT01416155 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT05532163 ·Status: TERMINATED ·Phase: PHASE4
-
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
NCT02021162 ·Status: COMPLETED
-
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512 ·Status: COMPLETED ·Phase: NA
-
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
NCT01485003 ·Status: COMPLETED
-
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
NCT01199640 ·Status: COMPLETED ·Phase: PHASE2
-
Natalizumab Temporary Discontinuation Study
NCT02775110 ·Status: COMPLETED ·Phase: PHASE4
-
Natalizumab Subcutaneous Immunogenicity and Safety Study
NCT02142192 ·Status: TERMINATED ·Phase: PHASE2
-
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
NCT00097331 ·Status: COMPLETED ·Phase: PHASE2
-
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
NCT03025269 ·Status: COMPLETED
-
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
NCT00035529 ·Status: TERMINATED ·Phase: PHASE2
-
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
NCT01395316 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
NCT02792218 ·Status: COMPLETED ·Phase: PHASE3